CGON
CG Oncology, Inc.
Next earnings Aug 6, 2026 · consensus $-0.68 EPS, $341K rev
Last earnings +0.6% on 2026-05-08
$68.72
▲ +4.55%$68.72▲ +161.49%
over 1Y
L $23.95EODHDH $74.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.5%
1W+13.7%
1M+11.0%
3M+4.4%
YTD+64.4%
1Y+161.5%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 22 analysts
Buy
Single-asset bladder-cancer biotech with a 2026 FDA decision pending — high-reward but binary, pre-revenue and not investable on fundamentals.
CG Oncology is a late-stage clinical biopharma whose entire value rests on one asset: cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). The science is genuinely promising — the 10-K reports 'potentially best-in-disease' Phase 3 data in BCG-unresponsive NMIBC, FDA Fast Track and Breakthrough Therapy designations, and a BLA initiated in Q4 2025 and expected to complete in 2026, addressing a market the company estimates at up to 150,000 patients across indications. A bladder-sparing alternative to radical cystectomy is a meaningful unmet need.
Sources: SEC EDGAR (CIK 0001991792, latest 10-Q filed 2026-05-08) · EODHD · analysis by claude-code · as of 6/21/2026, 8:57:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.